ClinicalTrials.gg
Not yet recruitingNCT07587814COCORIVOUpdated May 14, 2026

Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

An interventional study of 177Lu-PSMA-617 + SPECT/CT dosimetry in Carcinoma and Castration Resistant Prostatic Neoplasms, sponsored by Centre Henri Becquerel. Not yet recruiting at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Centre Henri Becquerel · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Carcinoma with a site in France — 20 open to participants now, 32 under way, 14 of them phase 3. Carcinoma · France.

Planned enrollment
54th of 86
100 · median 171
Started
2026
with 7 others
No phase
7 of 105
2 open now
Primary completion
2028-09
later than 23 of 31 live
Registered
103rd of 105
by date

Among the 105 studies in Carcinoma with a site in France, this one is the 54th largest by planned enrollment of the 86 interventional ones that give a count, is one of 8 that started in 2026, is one of 7 with no phase, reaches primary completion later than 23 of the 31 other live ones, and was the 103rd registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

20 of the 105 studies in Carcinoma with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Carcinoma with a site in France, or all of them as a file.
02

Study summary

COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.

Read the detailed description

Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic castration-resistant prostate cancer. 177Lu-PSMA-617 is a radioligand therapy delivering beta-particle radiation to PSMA-expressing cells. The VISION trial demonstrated significant improvement in progression-free and overall survival compared to standard of care.

Hypotheses: patients with higher fat mass may have better treatment response due to higher tumor dose; discordance between BMI-based and CT-based body composition measurements; SUV quantification in PET/CT and SPECT/CT depends on patient morphology; dosimetry of organs at risk depends on morphology; body composition changes during treatment; PSA kinetics are modified by dosimetry.

Study design: patients scheduled for 177Lu-PSMA treatment (4 or 6 cycles, 7400 MBq IV every 6 weeks) are enrolled. After cycle 1, SPECT/CT is performed at 72-96H (all patients) and additionally at 4-24H and 168-196H (40 patients for multipoint dosimetry). Body composition is extracted from the non-injected CT component of SPECT/CT using Anthropometer3DNet. Nutritional assessment (MNA questionnaire, blood tests including albumin, transthyretin, CRP, PSA) is performed at baseline (C1) and end of treatment (C4 or C6).

03

Conditions studied

  • Carcinoma
  • Castration Resistant Prostatic Neoplasms

Keywords

  • Lutetium-177
  • PSMA
  • Body composition
  • Dosimetry
  • Radioligand therapy
  • Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male, age >= 18 years
  • confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
  • PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT
  • Affiliated to or beneficiary of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)
  • Patient under legal protection (tutelle, curatelle, sauvegarde de justice)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    COCORIVO

    Patients with mCRPC treated with 177Lu-PSMA-617 undergoing additional SPECT/CT acquisitions and body composition analysis

    Radiation: 177Lu-PSMA-617 + SPECT/CT dosimetry

Interventions

  • Radiation177Lu-PSMA-617 + SPECT/CT dosimetry

    177Lu-PSMA-617 7400 MBq IV, 4 to 6 cycles every 6 weeks (standard of care). Additional interventions: whole-body SPECT/CT at 4-24H and/or 168-196H post-injection (research acquisitions) for dosimetry. Body composition analysis from SPECT/CT scanner using Anthropometer3DNet. MNA questionnaire and nutritional blood tests at baseline and end of treatment.

06

What researchers measure

Primary outcomes

  1. Tumor and organ-at-risk dosimetry as a function of body composition

    Dosimetry (Gy) of all tumors and organs at risk (salivary glands, bone marrow, kidneys) evaluated by SPECT/CT at 72-96H post-injection. Patients classified into two categories based on median body composition of the study population.

    Time frame: After cycle 1 of 177Lu-PSMA treatment (approximately week 1)

Secondary outcomes

  1. Comparison of SUV vs SUL in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT

    Comparison of SUV (normalized by total body mass) and SUL (normalized by lean body mass) of lesions and organs at risk. Difference \<20% considered equivalent.

    Time frame: Baseline and after cycle 1 (approximately week 1)

  2. Evaluate the differences between a single-point dosimetric approach based on population pharmacokinetics and a multi-point approach

    Comparison of dosimetry

    Time frame: 196 hours after the injection of the first cycle of 177LuPSMA

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2028, 24 months later.

Of 29 interventional studies with no phase under Carcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
May 14, 2026
StartEst.
Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Jun 2029
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587814
Lead sponsor
Centre Henri Becquerel
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Sep 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
May 14, 2026

Study contacts

Pierre Decazes, MD, PhD
Contact
pierre.decazes@chb.unicancer.fr
+33 2 76 67 30 59
Doriane Richard, PhD
Contact
doriane.richard@chb.unicancer.fr
+33 2 32 08 29 85

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion